Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice

被引:48
作者
Hoogendoorn, M
Feenstra, TL
Schermer, TRJ
Hesselink, AE
Rutten-van Mölken, MPMH
机构
[1] Erasmus MC, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands
[2] Natl Inst Publ Hlth & Environm, RIVM, Dept Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands
[3] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, EMGO, NL-1081 BT Amsterdam, Netherlands
关键词
COPD; epidemiology; disease severity; GOLD; general practice; diagnosis;
D O I
10.1016/j.rmed.2005.04.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The actual burden of chronic obstructive pulmonary disease (COPD) in terms of health care use and costs strongly depends on the distribution of disease severity. For the Netherlands, the distribution of diagnosed COPD was estimated by classifying all patients with a physician diagnosis of COPD from two different sources of general practitioners (GP)-data into mild (27%), moderate (55%), severe (15%) or very severe COPD (3%) based on their post-bronchodilator FEV1% predicted, according to the GOLD-guidelines. This distribution will most likely shift to the less severe stages when under-reporting and under-diagnosis are reduced. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:83 / 86
页数:4
相关论文
共 12 条
[1]  
[Anonymous], GLOB IN CHRON OBSTR
[2]   The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease [J].
Celli, BR ;
Cote, CG ;
Marin, JM ;
Casanova, C ;
de Oca, MM ;
Mendez, RA ;
Pinto Plata, V ;
Cabral, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :1005-1012
[3]   The impact of aging and smoking of the future burden of chronic obstructive pulmonary disease -: A model analysis in the Netherlands [J].
Feenstra, TL ;
van Genugten, MLL ;
Hoogenveen, RT ;
Wouters, EF ;
Rutten-van Mölken, MPMH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (04) :590-596
[4]   Pharmacoeconomic evaluation of COPD [J].
Hilleman, DE ;
Dewan, N ;
Malesker, M ;
Friedman, M .
CHEST, 2000, 118 (05) :1278-1285
[5]  
HOOGENDOORN M, 2003, HLTH POLICY MODEL CO
[6]   Costs of COPD in Sweden according to disease severity [J].
Jansson, SA ;
Andersson, F ;
Borg, S ;
Ericsson, Å ;
Jönsson, E ;
Lundbäck, B .
CHEST, 2002, 122 (06) :1994-2002
[7]  
Lamberts H., 1987, ICPC INT CLASSIFICAT
[8]   Costs of chronic bronchitis and COPD - A 1-year follow-up study [J].
Miravitlles, M ;
Murio, C ;
Guerrero, T ;
Gisbert, R .
CHEST, 2003, 123 (03) :784-791
[9]   Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study [J].
Murray, CJL ;
Lopez, AD .
LANCET, 1997, 349 (9064) :1498-1504
[10]   LUNG-VOLUMES AND FORCED VENTILATORY FLOWS - REPORT WORKING PARTY STANDARDIZATION OF LUNG-FUNCTION TESTS EUROPEAN-COMMUNITY FOR STEEL AND COAL - OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY [J].
QUANJER, PH ;
TAMMELING, GJ ;
COTES, JE ;
PEDERSEN, OF ;
PESLIN, R ;
YERNAULT, JC .
EUROPEAN RESPIRATORY JOURNAL, 1993, 6 :5-40